Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men

Journal of Nutrition

Volumn 141, Issue 2, 2011, Pages 267-273

  Maserejian, Nancy N ^a   Giovannucci, Edward L ^b,c   McVary, Kevin T ^d   McKinlay, John B ^a  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ASCORBIC ACID; BETA CAROTENE; BETA CRYPTOXANTHIN; CAROTENOID; IRON; LYCOPENE; RETINOL; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CROSS-SECTIONAL STUDY; DIETARY INTAKE; DISEASE SEVERITY; HUMAN; IRON INTAKE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ASCORBIC ACID; CAROTENOIDS; CROSS-SECTIONAL STUDIES; DIET; DIETARY SUPPLEMENTS; HUMANS; INTERVIEWS AS TOPIC; IRON, DIETARY; LOGISTIC MODELS; MALE; MALE UROGENITAL DISEASES; MASSACHUSETTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; RISK FACTORS; SMOKING; URINARY TRACT; URINATION; VITAMIN A;

EID: 79251473393     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.110.132514     Document Type: Article

References (65)

1. Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, Link CL, McKinlay JB. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006;166:2381-7.
2. Litman HJ,McKinlay JB. The future magnitude of urological symptoms in the USA: projections using the Boston Area Community Health survey. BJU Int. 2007;100:820-5.
3. Poon KS, McVary KT. Dietary patterns, supplement use, and the risk of benign prostatic hyperplasia. Curr Urol Rep. 2009;10:279-86.
4. Azadzoi KM, Yalla SV, Siroky MB. Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol. 2007;178:710-5.
5. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51:1202-16.
6. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174:1327-433.
7. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178:395-401.
8. Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int. 2005;96:88-92.
9. Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2004;159:390-7.
10. Cinar A, Hall SA, Link CL, Kaplan SA, Kopp ZS, Roehrborn CG, Rosen RC. Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey. BJU Int. 2008;101:1247-56.
11. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;167:925-34.
12. Maserejian NN, Giovannucci EL, McKinlay JB. Dietary macronutrients, cholesterol, and sodium and lower urinary tract symptoms in men. Eur Urol. 2009;55:1179-89.
13. Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr. 2002;75:689-97.
14. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys. 1989;274: 532-8.
15. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. JAMA. 1999;281:1415-23.
16. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-5.
17. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842-57.
18. Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, Leitzmann MF. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst. 2007;99:754-64.
19. Maserejian NN, Giovannucci E, Rosner B, Joshipura K. Prospective study of vitamins C, E, and A and carotenoids and risk of oral premalignant lesions in men. Int J Cancer. 2007;120:970-7.
20. Lavin JM, Hosker GL, Smith AR. Does urinary pH influence micturition desire? Neurourol Urodyn. 1997;16:396-7.
21. Lee F, Oliver S, Susser J, Mundy AR, CraggsMD, Foxall PJD. The effect of urine composition on sensations of urinary urge. BJU Int. 2001;88:287-8.
22. Koskimaki J, Hakama M, Huhtala H, Tammela TL. Association of dietary elements and lower urinary tract symptoms. Scand J Urol Nephrol. 2000;34:46-50.
23. Lagiou P, Wuu J, Trichopoulou A, Hsieh CC, Adami HO, Trichopoulos D. Diet and benign prostatic hyperplasia: a study in Greece. Urology. 1999;54:284-90.
24. Tavani A, Longoni E, Bosetti C, Maso LD, Polesel J, Montella M, Ramazzotti V, Negri E, Franceschi S, et al. Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: a case-control study from Italy. Eur Urol. 2006;50:549-54.
25. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between serum concentrations of micronutrients and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey. Urology. 2004;64:504-9.
26. Rohrmann S, Giovannucci E, Willett WC, Platz EA. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr. 2007;85:523-9.
27. McKinlay JB, Link CL. Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey. Eur Urol. 2007;52:389-96.
28. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L. A data-based approach to diet questionnaire design and testing. Am J Epidemiol. 1986;124:453-69.
29. Block G, Wakimoto P, Jensen C, Mandel S, Green RR. Validation of a food frequency questionnaire for Hispanics. Prev Chronic Dis. 2006;3: A77.
30. Subar AF, Thompson FE, Kipnis V, Midthune D, Hurwitz P, McNutt S, McIntosh A, Rosenfeld S. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. Am J Epidemiol. 2001;154:1089-99.
31. Boucher B, Cotterchio M, Kreiger N, Nadalin V, Block T, Block G. Validity and reliability of the Block98 food-frequency questionnaire in a sample of Canadian women. Public Health Nutr. 2006;9:84-93.
32. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148: 1549-57, discussion 64.
33. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs FD, Fourcade R, Kiemeney L, Lee C. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int. 2003;92:409-14.
34. Chai TC, Belville WD, McGuire EJ, Nyquist L. Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol. 1993;150: 1710-3.
35. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr. 1997;65:S1220-8; discussion S9-31.
36. Willett WC. Issues in analysis and presentation of dietary data. In: Willett WC, editor. Nutritional epidemiology. 2nd ed. New York: Oxford University Press; 1998.
37. Lee KW, Lee HJ, Surh YJ, Lee CY. Vitamin C and cancer chemoprevention: reappraisal. Am J Clin Nutr. 2003;78:1074-8.
38. Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46:153-62.
39. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J. 1999;13:1007-24.
40. Chen K, Suh J, Carr AC, Morrow JD, Zeind J, Frei B. Vitamin C suppresses oxidative lipid damage in vivo, even in the presence of iron overload. Am J Physiol Endocrinol Metab. 2000;279:E1406-12.
41. Paolini M, Pozzetti L, Pedulli GF, Marchesi E, Cantelli-Forti G. The nature of prooxidant activity of vitamin C. Life Sci. 1999;64:PL 273-8.
42. Matos HR, Marques SA, Gomes OF, Silva AA, Heimann JC, Di Mascio P, Medeiros MH. Lycopene and beta-carotene protect in vivo iron-induced oxidative stress damage in rat prostate. Braz J Med Biol Res. 2006;39:203-10.
43. Schwarz S, Obermuller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr. 2008;138:49-53.
44. Clinton SK, Emenhiser C, Schwartz SJ, Bostwick DG,Williams AW,Moore BJ, Erdman JW Jr. cis-trans Lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev. 1996;5:823-33.
45. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-84.
46. Riso P, Brusamolino A, Martinetti A, Porrini M. Effect of a tomato drink intervention on insulin-like growth factor (IGF)-1 serum levels in healthy subjects. Nutr Cancer. 2006;55:157-62.
47. Walfisch S, Walfisch Y, Kirilov E, Linde N, Mnitentag H, Agbaria R, Sharoni Y, Levy J. Tomato lycopene extract supplementation decreases insulin-like growth factor-I levels in colon cancer patients. Eur J Cancer Prev. 2007;16:298-303.
48. Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate. 2002;52:98-105.
49. Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate. 2008;68: 1477-86.
50. Erdman JW Jr, Ford NA, Lindshield BL. Are the health attributes of lycopene related to its antioxidant function? Arch Biochem Biophys. 2009;483:229-35.
51. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;168:1416-24.
52. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, Smit E, Giovannucci E, Platz EA. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology. 2007;69:708-13.
53. Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int. 2007;100:321-6.
54. Choi JY, Neuhouser ML, Barnett MJ, Hong CC, Kristal AR, Thornquist MD, King IB, Goodman GE, Ambrosone CB. Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis. 2008;29:964-70.
55. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem. 2005;12:1161-208.
56. Terry KL, Missmer SA, Hankinson SE,Willett WC, De Vivo I. Lycopene and other carotenoid intake in relation to risk of uterine leiomyomata. Am J Obstet Gynecol. 2008;198:37 e1-8.
57. Touvier M, Kesse E, Clavel-Chapelon F, Boutron-Ruault MC. Dual association of beta-carotene with risk of tobacco-related cancers in a cohort of French women. J Natl Cancer Inst. 2005;97:1338-44.
58. Paolini M, Abdel-Rahman SZ, Sapone A, Pedulli GF, Perocco P, Cantelli-Forti G, Legator MS. Beta-carotene: a cancer chemopreventive agent or a co-carcinogen? Mutat Res. 2003;543:195-200.
59. Russell RM. The enigma of beta-carotene in carcinogenesis: what can be learned from animal studies. J Nutr. 2004;134:S262-8.
60. Birder LA, Kanai AJ, Cruz F, Moore K, Fry CH. Is the urothelium intelligent? Neurourol Urodyn. 2010;29:598-602.
61. Huang MH, Schocken M, Block G, Sowers M, Gold E, Sternfeld B, Seeman T, Greendale GA. Variation in nutrient intakes by ethnicity: results from the Study of Women's Health Across the Nation (SWAN). Menopause. 2002;9:309-19.
62. Signorello LB, Buchowski MS, Cai Q, Munro HM, Hargreaves MK, Blot WJ. Biochemical validation of food frequency questionnaire-estimated carotenoid, alpha-tocopherol, and folate intakes among African Americans and non-Hispanic Whites in the Southern Community Cohort Study. Am J Epidemiol. 2010;171:488-97.
63. Talegawkar SA, Johnson EJ, Carithers TC, Taylor HA, Bogle ML, Tucker KL. Carotenoid intakes, assessed by food-frequency questionnaires (FFQs), are associated with serum carotenoid concentrations in the Jackson Heart Study: validation of the Jackson Heart Study Delta NIRI Adult FFQs. Public Health Nutr. 2008;11:989-97.
64. Brown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K, Mundy A, Newman SP, van der Meulen J, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ. 2007; 334:25.
65. Yap TL, Brown CT, Emberton M. Self-management in lower urinary tract symptoms: the next major therapeutic revolution. World J Urol. 2006;24:371-7.